V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007161 | 10009258 | 0 | 83.3 | Palliative (P) | 2018-08-28 | 2018-08-28 | Enzalutamide | N | N | 10508420 | AFLIBERCEPT + FU + IRINOTECAN |
| 10007162 | 10009258 | null | null | Palliative (P) | 2017-09-12 | 2017-09-19 | Capecitabine + Mitomycin | null | N | 10508420 | CETUXIMAB |
| 10007163 | 10004998 | 1.75 | 84.8 | Palliative (P) | 2016-12-16 | 2019-01-09 | Fluorouracil96hr infusion+RT(3g/m2) | null | N | 10508471 | BORTEZOMIB + THALIDOMIDE |
| 10007164 | 10004999 | 1.72 | null | Palliative (P) | 2017-12-27 | 2017-12-27 | CISPLATIN + GEMCITABINE | N | null | 10508471 | EOX |
| 10007165 | 10005002 | 1.7 | null | Disease modification (D) | 2015-11-07 | 2015-11-07 | Sunitinib | N | N | 10508708 | IMATINIB |
| 10007166 | 10005002 | 1.87 | 77.4 | Disease modification (D) | 2018-04-06 | 2018-04-07 | Bortezomib +/- Dexamethasone | N | N | 10508708 | CERITINIB |
| 10007167 | 10005002 | 1.58 | 76.8 | Palliative (P) | 2017-04-30 | 2017-05-23 | Gemcitabine + Capecitabine | N | N | 10508708 | CMV |
| 10007168 | 10005006 | 1.79 | 86 | Palliative (P) | 2015-06-08 | 2015-07-21 | TOPOTECAN | 2 | N | 10508910 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10007169 | 10005007 | 1.72 | 75.1 | null | 2016-08-22 | 2017-04-08 | AFATINIB | 02 | N | 10509039 | GDP |
| 10007170 | 10005008 | null | 75.4 | Palliative (P) | 2017-03-14 | 2017-03-22 | Erlotinib | N | N | 10509088 | BORTEZOMIB |
| 10007171 | 10005009 | 1.64 | 73 | Curative (C) | 2014-07-12 | 2014-07-14 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 02 | N | 10509088 | PACLITAXEL + TRASTUZUMAB |
| 10007172 | 10008592 | 1.67 | 65.8 | Palliative (P) | 2018-08-10 | 2018-08-15 | LANREOTIDE | N | N | 10509279 | CARBOPLATIN + LIPOSOMAL DOX |
| 10007173 | 10005013 | 1.62 | 56.4 | null | 2015-05-14 | 2015-05-15 | Vinblastine | 2 | N | 10509302 | CAPECITABINE + CISPLATIN + RT |
| 10007174 | 10005013 | 1.75 | 60.8 | Palliative (P) | 2018-06-28 | 2018-06-28 | Vinorelbine (oral) | N | N | 10509302 | CVD |
| 10007175 | 10005013 | 1.76 | 79.8 | Disease modification (D) | 2016-05-20 | 2016-06-11 | Ofatumumab Monthly | 2 | N | 10509302 | CAPECITABINE + GEMCITABINE |
| 10007176 | 10005015 | 1.61 | null | Palliative (P) | 2015-10-02 | 2015-10-18 | Bortezomib (weekly) | N | n | 10509678 | DOCETAXEL + NINTEDANIB |
| 10007177 | 10007521 | 1.59 | 81 | Palliative (P) | 2016-12-09 | 2016-12-23 | FLAIR Trial | N | N | 10509722 | DOCETAXEL + TRASTUZUMAB |
| 10007178 | 10007521 | 1.67 | 75.1 | Palliative (P) | 2017-07-28 | 2017-09-08 | Capecitabine + Cisplatin + RT | 02 | N | 10509722 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN |
| 10007179 | 10005018 | 1.58 | null | Palliative (P) | 2016-02-02 | 2016-02-16 | IMATINIB | N | n | 10509834 | CISPLATIN + ETOPOSIDE |
| 10007180 | 10005020 | 1.73 | 69.5 | Palliative (P) | 2018-05-30 | 2018-05-31 | EOX | N | Y | 10509858 | PMITCEBO |
| 10007181 | 10005021 | 1.65 | 70 | null | 2018-10-03 | 2018-10-17 | Mitomycin Intravesical | 02 | N | 10509858 | CABOZANTINIB |
| 10007182 | 10005022 | 1.75 | 66.4 | Curative (C) | 2015-12-23 | 2015-12-31 | EOX | 2 | N | 10510047 | GDP |
| 10007183 | 10005024 | 1.76 | 75.4 | Palliative (P) | 2015-03-02 | 2015-03-08 | Hydroxycarbamide | 2 | N | 10510063 | AFATINIB |
| 10007184 | 10005027 | 1.71 | 82 | Radical (R) | 2017-05-29 | 2017-05-29 | Vinorelbine (oral) | 02 | N | 10510063 | BORTEZOMIB |
| 10007185 | 10005028 | 1.58 | 57 | Not known (9) | 2017-11-01 | 2017-12-02 | Erlotinib | 02 | N | 10510595 | VEDEX |
| 10007186 | 10005029 | 1.64 | null | Palliative (P) | 2018-09-08 | 2018-11-15 | MPT | 02 | N | 10510691 | FLUOROURACIL + MITOMYCIN + RT |
| 10007187 | 10005030 | 1.61 | null | Palliative (P) | 2013-05-24 | 2013-05-29 | Liposomal Doxorubicin 50mg/m2 | N | null | 10510953 | ERLOTINIB |
| 10007188 | 10007525 | null | 105.7 | Palliative (P) | 2016-04-09 | 2016-04-11 | Busulfan Oral | 02 | N | 10511121 | OBINUTUZUMAB |
| 10007189 | 10007525 | 1.77 | 78.5 | null | 2014-05-01 | 2014-05-20 | Cytarabine intrathecal | N | null | 10511121 | METHOTREXATE HIGH DOSE |
| 10007190 | 10005032 | 1.75 | 66.5 | Neo-adjuvant (N) | 2016-07-19 | 2016-07-19 | ECF | 02 | N | 10511258 | CHOP |
| 10007191 | 10005034 | null | 65.5 | Palliative (P) | 2014-11-16 | 2014-12-01 | Cetuximab + FOLFIRI cycle 2 onwards | null | N | 10511315 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 10007192 | 10005034 | 1.68 | 64.4 | Disease modification (D) | 2015-12-21 | 2016-01-13 | CHLORAMBUCIL + OBINUTUZUMAB | 2 | N | 10511315 | EOF |
| 10007193 | 10005034 | 1.72 | 82.7 | Neo-adjuvant (N) | 2017-07-11 | 2017-07-28 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | 10511315 | IDARUBICIN |
| 10007194 | 10005037 | 1.78 | null | Palliative (P) | 2017-03-25 | 2017-05-28 | Capecitabine + Mitomycin | N | N | 10512209 | BORTEZOMIB |
| 10007195 | 10005038 | 0 | 75.5 | Neo-adjuvant (N) | 2016-10-16 | 2016-12-05 | Enzalutamide | N | N | 10512226 | RUXOLITINIB |
| 10007196 | 10005039 | null | 111 | Curative (C) | 2014-10-05 | 2014-10-26 | Cytarabine intrathecal | 2 | N | 10512345 | FLAG + IDARUBICIN |
| 10007197 | 10005042 | 1.55 | 79.4 | Palliative (P) | 2016-02-03 | 2016-02-04 | CARBOPLATIN + PACLITAXEL + RT | 2 | N | 10512604 | IMATINIB |
| 10007198 | 10005044 | 0 | 73.6 | Palliative (P) | 2018-04-14 | 2018-04-21 | AML16 DA 3+8 | N | N | 10512604 | BENDAMUSTINE |
| 10007199 | 10005045 | 1.77 | 101.4 | Neo-adjuvant (N) | 2015-10-26 | 2015-11-01 | AFATINIB | N | N | 10512994 | MELPHALAN |
| 10007200 | 10005046 | 1.69 | 93 | Palliative (P) | 2018-09-04 | 2018-09-10 | GEMCITABINE + OXALIPLATIN + PACLITAXEL | N | N | 10513178 | AML16 TRIAL |
| 10007201 | 10007530 | 1.72 | 77.9 | Palliative (P) | 2016-07-17 | 2016-07-17 | Cisplatin+Gemcitabine (gallbladder) | 2 | N | 10513468 | CISPLATIN + RT |
| 10007202 | 10005047 | 1.82 | null | Disease modification (D) | 2015-03-19 | 2015-05-12 | Procarbazine | N | N | 10513618 | CETUXIMAB + IRINOTECAN + MDG |
| 10007203 | 10005047 | 1.81 | null | Adjuvant (A) | 2016-04-20 | 2016-04-18 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | 10513618 | CHLORAMBUCIL |
| 10007204 | 10005048 | 1.66 | 49.4 | Palliative (P) | null | 2017-09-02 | Lomustine | N | N | 10513816 | CAPECITABINE + IRINOTECAN |
| 10007205 | 10005049 | 1.87 | 88.5 | Curative (C) | 2015-12-18 | 2016-05-08 | NIVOLUMAB | 2 | N | 10513915 | METHOTREXATE HIGH DOSE |
| 10007206 | 10005049 | 1.65 | 49.25 | Palliative (P) | 2016-02-09 | 2016-02-09 | CAPECITABINE + RT | 02 | N | 10513915 | CAPECITABINE + IRINOTECAN |
| 10007207 | 10005049 | 1.8 | 83.5 | Palliative (P) | 2016-05-01 | 2016-06-17 | AFATINIB | 2 | N | 10513915 | CETUXIMAB |
| 10007208 | 10005049 | 1.68 | 74.7 | Palliative (P) | 2015-12-24 | 2016-01-22 | Cape+Cisplatin+Trastuzumab Main | 02 | N | 10513915 | CYTARABINE HIGH DOSE |
| 10007209 | 10005049 | 1.69 | 96.1 | Palliative (P) | 2017-11-29 | 2017-11-29 | Pazopanib | 02 | N | 10513915 | CARBO + FLUOROURACIL |
| 10007210 | 10005050 | null | 62.2 | Palliative (P) | 2017-01-14 | 2017-01-17 | ATG + Busulfan + Fludarabine | 02 | N | 10514415 | OSIMERTINIB |